Key Takeaways:Galderma's private equity backers have been taking advantage of the stock’s rally to offload shares despite recent market turmoil.Since March 2024, the stock has nearly tripled, rising 82% from its IPO price.Galderma floated on the SIX Swiss Exchange in March 2024, achieving the largest IPO placement volume in Switzerland since 2017.A trio of Galderma shareholders exited their remaining 14.3% stake in the Swiss skincare company in the largest-ever overnight share sale in Switzerland. EQT AB, Abu Dhabi Investment Authority, and Auba Investment Pte. sold 34 million shares in an overnight trade valued at $6.3 billion.Galderma was spun out of Nestlé in 2019 when a consortium led by private equity house EQT and including Singapore's GIC and the Abu Dhabi Investment Authority acquired the Nestlé Skin Health unit for $10 billion and rebranded it as Galderma. Since its inception in 1981, the business has been driven by a dedication to dermatology, delivering an innovative, science-based portfolio of sophisticated brands and services across aesthetics, consumer care, and prescription medicine. Galderma’s portfolio of flagship brands includes Restylane, Dysport, Azzalure, Alluzience, and Sculptra in injectable aesthetics; Cetaphil and Alastin in dermatological skincare; and Soolantra, Epiduo, Differin, Aklief, Epsolay, Twyneo, Oracea, Metvix, Benzac, and Loceryl in therapeutic dermatology. Galderma has more than doubled in size, growing from a €1.6 billion ($1.7 billion) to a €4.4 billion ($4.8 billion) company in 2024.DETAILS:The buyout group of EQT AB, Abu Dhabi Investment Authority, and Auba Investment Pte. sold 34 million existing shares and raised 4.